知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.07 秒)

    Method of combating infection
    2.
    发明申请
    Method of combating infection 失效
    抗感染方法

    公开(公告)号：US20100273762A1

    公开(公告)日：2010-10-28

    申请号：US11991080

    申请日：2006-09-04

    申请人： Philip John Burke ,  Roger Melton ,  Richard John Knox

    发明人： Philip John Burke ,  Roger Melton ,  Richard John Knox

    IPC分类号： A61K31/396 ,  C07D203/04 ,  A61P33/02

    CPC分类号： A61K31/396 ,  Y02A50/409 ,  Y02A50/414 ,  Y02A50/488

    摘要： A method of combating a parasitic protozoal infection of a host organism, the method comprising administering tretazicar to the host organism. Tretazicar is the compound 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954), and the parasitic infection is preferably an infection of Trypanosoma cruzi, T. b. brucei, Leishmania spp. particularly L. infantum, Cryptosporidium or Giardia spp.

    摘要翻译： 一种抵抗宿主生物体的寄生原虫感染的方法，所述方法包括向所述宿主生物体施用噻托他汀。 Tretazicar是5-（吖啶啶-1-基）-2,4-二硝基苯甲酰胺（CB 1954）的化合物，寄生虫感染优选为克氏锥虫感染T. 布鲁斯，利什曼原虫属 特别是婴幼儿，隐孢子虫或贾第虫属。

    Therapeutic systems
    3.
    发明授权
    Therapeutic systems 失效

    公开(公告)号：US07138122B2

    公开(公告)日：2006-11-21

    申请号：US10099830

    申请日：2002-03-13

    申请人： Philip John Burke ,  Richard John Knox

    发明人： Philip John Burke ,  Richard John Knox

    IPC分类号： A01N43/00 ,  A61K31/33

    CPC分类号： C12N9/0036 ,  A61K31/455 ,  A61K38/00 ,  A61K47/6815 ,  A61K47/6899 ,  A61K48/005 ,  B82Y5/00 ,  C07K2319/74

    摘要： A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug, or a polynucleotide encoding said NQO2 or said variant or fragment or fusion or derivative. A recombinant polynucleotide comprising a target cell-specific promoter operably linked to a polynucleotide encoding human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug. The compounds and polynucleotides are useful in a method of treating a patient in conjunction with a suitable prodrug. A method of treating a human patient with a target cell to be destroyed wherein the target cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a substantially cytotoxic drug by the action of NQO2 and nicotinamide riboside (reduced) (NRH) or an analogue thereof which can pass reducing equivalents to NQO2.

    Therapeutic systems
    4.
    发明授权
    Therapeutic systems 失效
    治疗系统

    公开(公告)号：US06867231B1

    公开(公告)日：2005-03-15

    申请号：US09445865

    申请日：1998-06-15

    申请人： Philip John Burke ,  Richard John Knox

    发明人： Philip John Burke ,  Richard John Knox

    IPC分类号： C12N15/09 ,  A61K31/455 ,  A61K31/711 ,  A61K45/00 ,  A61K47/22 ,  A61K47/48 ,  A61K48/00 ,  A61P35/00 ,  A01N47/10 ,  A01N43/00 ,  A61K31/785

    CPC分类号： C12N9/0036 ,  A61K31/455 ,  A61K38/00 ,  A61K47/6815 ,  A61K47/6899 ,  A61K48/005 ,  B82Y5/00 ,  C07K2319/74

    摘要： A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug, or a polynucleotide encoding said NQO2 or said variant or fragment or fusion or derivative. A recombinant polynucleotide comprising a target cell-specific promoter operably linked to a polynucleotide encoding human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug. The compounds and polynucleotides are useful in a method of treating a patient in conjunction with a suitable prodrug. A method of treating a human patient with a target cell to be destroyed wherein the target cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a substantially cytotoxic drug by the action of NQO2 and nicotinamide riboside (reduced) (NRH) or an analogue thereof which can pass reducing equivalents to NQO2.

    摘要翻译： 包含目标细胞特异性部分和人NAD（P）H：醌还原酶2（NQO2）或其与NQO2具有与给定前药基本相同的活性的变体或片段或融合物或衍生物的化合物或编码 所述NQO2或所述变体或片段或融合物或衍生物。 一种重组多核苷酸，其包含与编码人NAD（P）H：醌还原酶2（NQO2）的多核苷酸或其变体或片段或融合物或衍生物可操作地连接的靶细胞特异性启动子，其与NQO2具有基本相同的活性 前药。 化合物和多核苷酸可用于与合适的前药联合治疗患者的方法。 一种用待破坏的靶细胞治疗人类患者的方法，其中靶细胞表达NQO2，该方法包括向患者施用通过NQO2和烟酰胺核苷（还原）（NRH）的作用将其转化为基本上细胞毒性药物的前药 ）或其类似物，其可以通过还原当量到NQO 2。